223 related articles for article (PubMed ID: 25872564)
41. Oxaliplatin-induced renal tubular vacuolization.
Joybari AY; Sarbaz S; Azadeh P; Mirafsharieh SA; Rahbari A; Farasatinasab M; Mokhtari M
Ann Pharmacother; 2014 Jun; 48(6):796-800. PubMed ID: 24615628
[TBL] [Abstract][Full Text] [Related]
42. The effect of diabetes on oxaliplatin-induced peripheral neuropathy.
Uwah AN; Ackler J; Leighton JC; Pomerantz S; Tester W
Clin Colorectal Cancer; 2012 Dec; 11(4):275-9. PubMed ID: 22682776
[TBL] [Abstract][Full Text] [Related]
43. Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent.
Vietor NO; George BJ
J Oncol Pharm Pract; 2012 Sep; 18(3):355-9. PubMed ID: 22333669
[TBL] [Abstract][Full Text] [Related]
44. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients.
Tonini G; Santini D; Vincenzi B; Borzomati D; Dicuonzo G; La Cesa A; Onori N; Coppola R
J Biol Regul Homeost Agents; 2002; 16(2):105-9. PubMed ID: 12144121
[TBL] [Abstract][Full Text] [Related]
45. A midline for oxaliplatin infusion: the myth of safety devices.
Masters B; Hickish T; Cidon EU
BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24903726
[TBL] [Abstract][Full Text] [Related]
46. Oxaliplatin-induced immune pancytopenia.
Taleghani BM; Meyer O; Fontana S; Ahrens N; Novak U; Borner MM; Salama A
Transfusion; 2005 May; 45(5):704-8. PubMed ID: 15847658
[TBL] [Abstract][Full Text] [Related]
47. Fatal thrombocytopenia after oxaliplatin-based chemotherapy.
Shao YY; Hong RL
Anticancer Res; 2008; 28(5B):3115-7. PubMed ID: 19031966
[TBL] [Abstract][Full Text] [Related]
48. Exacerbation of oxaliplatin neurosensory toxicity following surgery.
Gornet JM; Savier E; Lokiec F; Cvitkovic E; Misset JL; Goldwasser F
Ann Oncol; 2002 Aug; 13(8):1315-8. PubMed ID: 12181257
[TBL] [Abstract][Full Text] [Related]
49. Transient elastography for the prediction of oxaliplatin-associated liver injury in colon cancer patients: a preliminary analysis.
Oki E; Kakeji Y; Taketomi A; Yamashita Y; Ohgaki K; Harada N; Iguchi T; Shibahara K; Sadanaga N; Morita M; Maehara Y
J Gastrointest Cancer; 2008; 39(1-4):82-5. PubMed ID: 19377909
[TBL] [Abstract][Full Text] [Related]
50. Recurrent priapism related to oxaliplatin infusion.
Adenis A; Mailliez A; Rigot JM; Gamelin L; Vanhuyse M; Gamelin E
J Clin Oncol; 2008 Feb; 26(6):1016-7. PubMed ID: 18281680
[No Abstract] [Full Text] [Related]
51. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?
Elligers KT; Davies M; Sanchis D; Ferencz T; Saif MW
JOP; 2008 Mar; 9(2):197-202. PubMed ID: 18326929
[TBL] [Abstract][Full Text] [Related]
52. Sudden bilateral sensorineural hearing loss after intravenous cocaine injection: a case report and review of the literature.
Stenner M; Stürmer K; Beutner D; Klussmann JP
Laryngoscope; 2009 Dec; 119(12):2441-3. PubMed ID: 19806646
[TBL] [Abstract][Full Text] [Related]
53. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?
James E; Podoltsev N; Salehi E; Curtis BR; Saif MW
Clin Colorectal Cancer; 2009 Oct; 8(4):220-4. PubMed ID: 19822513
[TBL] [Abstract][Full Text] [Related]
54. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis.
Koutras AK; Makatsoris T; Paliogianni F; Kopsida G; Onyenadum A; Gogos CA; Mouzaki A; Kalofonos HP
Oncology; 2004; 67(2):179-82. PubMed ID: 15539924
[TBL] [Abstract][Full Text] [Related]
55. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
[TBL] [Abstract][Full Text] [Related]
56. Oxaliplatin-induced proximal renal tubular acidosis.
Negro A; Grasselli C; Galli P
Intern Emerg Med; 2010 Jun; 5(3):267-8. PubMed ID: 19937480
[No Abstract] [Full Text] [Related]
57. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine.
Durand JP; Brezault C; Goldwasser F
Anticancer Drugs; 2003 Jul; 14(6):423-5. PubMed ID: 12853883
[TBL] [Abstract][Full Text] [Related]
58. Ocular changes with oxaliplatin.
O'Dea D; Handy CM; Wexler A
Clin J Oncol Nurs; 2006 Apr; 10(2):227-9. PubMed ID: 16708705
[TBL] [Abstract][Full Text] [Related]
59. Oxaliplatin-related neurotoxicity: how and why?
Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
[TBL] [Abstract][Full Text] [Related]
60. Oxaliplatin-induced acute thrombocytopenia: a case report and review of the literature.
Suzuki K; Oda H; Sugawara Y; Masuya M; Nakase K; Fujioka M; Imai H; Katayama N
Intern Med; 2013; 52(5):611-5. PubMed ID: 23448774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
